title: Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.
abstract: The treatment of metastatic colorectal cancer with modern cytotoxic agents in combination with monoclonal antibodies against vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR) has improved median overall survival from 6 months to almost 2 years. Uncertainty remains over the optimal chemotherapy combination and sequencing, and to which line of treatment monoclonal antibodies should be added. This article reviews the rationale and evidence for the use of monoclonal antibodies in the first-line treatment of metastatic colorectal cancer in both general and specific situations, and provides a perspective on how to position their use in contemporary practice.
authors.affiliation: Gastrointestinal and Lymphoma Units, Royal Marsden Hospital London and Surrey, Downs Road, Sutton, Surrey, United Kingdom.
authors.forename: Christopher
authors.initials: C
authors.lastname: Jackson
authors.forename: David
authors.initials: D
authors.lastname: Cunningham
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D066246:ErbB Receptors / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D042461:Vascular Endothelial Growth Factor A; D000077150:Oxaliplatin; D000068258:Bevacizumab; D000077146:Irinotecan; D066246:ErbB Receptors; D002166:Camptothecin